Trial Profile
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Seviprotimut-L (Primary) ; Seviprotimut-L (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms MAVIS
- Sponsors Polynoma
- 11 Jan 2022 According to Polynoma media release, final analysis of Part B1 data were published in the Journal for ImmunoTherapy of Cancer (JITC).
- 30 Jun 2021 Status changed from active, no longer recruiting to discontinued.
- 23 Jun 2020 Results of final analysis of clinical data from Part B1 of this study, presented in a Polynoma media release.